GlaxoSmithKline plc : GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash
09/13/2012| 08:29am US/Eastern
Recommend:
This press release is intended for business journalists and
analysts/investors. Please note that this release may not
have been issued in every market in which GSK operates.
Issued: Thursday 13 September 2012, London, UK
GlaxoSmithKline plc (LSE: GSK) today announces that it has
acquired five million newly issued shares of Response
Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase
price of US$1.10 per share in cash. As a result, GSK now owns
approximately 15.2% of the expanded share capital of RGI.
This transaction builds on the relationship GSK and RGI have
been building over the years in the diagnostics field of
oncology and vaccines. RGI performs companion diagnostic
tests and other related activities for GSK's immunotherapies
and oncology pipeline candidates.
GlaxoSmithKline - one of the world's leading research-based
pharmaceutical and healthcare companies - is committed to
improving the quality of human life by enabling people to do
more, feel better and live longer. For further
information please visit www.gsk.com
|
GlaxoSmithKline Enquiries:
|
|
|
|
|
UK Media enquiries:
|
David Mawdsley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Stephen Rea
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Sarah Spencer
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
David Daley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
|
|
|
|
US Media enquiries:
|
Kevin Colgan
|
+1 919 483 2933
|
(North Carolina)
|
|
|
Melinda Stubbee
|
+1 919 483 2510
|
(North Carolina)
|
|
|
Sarah Alspach
|
+1 202 715 1048
|
(Washington, DC)
|
|
|
Jennifer Armstrong
|
+1 215 751 5664
|
(Philadelphia)
|
|
|
|
|
|
|
Analyst/Investor enquiries:
|
Sally Ferguson
|
+44 (0) 20 8047 5543
|
(London)
|
|
|
Tom Curry
|
+ 1 215 751 5419
|
(Philadelphia)
|
|
|
Gary Davies
|
+ 44 (0) 20 8047 5503
|
(London)
|
|
|
James Dodwell
|
+ 44 (0) 20 8047 2406
|
(London)
|
|
|
Jeff McLaughlin
|
+ 1 215 751 7002
|
(Philadelphia)
|
|
|
Ziba Shamsi
|
+ 44 (0) 20 8047 3289
|
(London)
|
GlaxoSmithKline cautionary statement regarding
forward-looking statements
Under the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995, GSK cautions
investors that any forward-looking statements or projections
made by GSK, including those made in this announcement, are
subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Factors
that may affect GSK' s operations are described under
'Risk factors' in the 'Financial review &
risk' section in the company's Annual Report 2011
included as exhibit 15.2 to the company's Annual Report
on Form 20-F for 2011.
distributed by
|
|
Recommend :
